Abstract: Provided are a composition and a complex formulation, each including insulin or a long-acting conjugate thereof and glucagon or a long-acting conjugate thereof.

Abstract: The present invention relates to therapeutic uses of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors, and long-acting conjugates thereof for liver disease.

Abstract: A long-acting conjugate for brain targeting is disclosed. The long-acting conjugate includes a peptide for brain targeting and a physiologically active material. The long-acting conjugate contains a physiologically active material with improved durability and stability, which can pass through the blood-brain barrier (BBB) and comprises a physiologically active material. The long-acting conjugate for brain targeting including a peptide for brain targeting and a physiologically active material can pass through the blood-brain barrier, thus enabling the treatment of diseases associated with brain diseases, and additionally, can maintain the activity of a physiologically active material in vivo and increase its half-life in the blood.

Abstract: Provided are a protein conjugate in which a physiologically active polypeptide is linked to a biocompatible material via a non-peptidyl polymer-coupled fatty acid derivative compound serving as a linker, exhibiting an increased duration of physiological activity compared to natural forms and a preparation method therefor. Since an increase in serum half-life of the physiologically active polypeptide of the protein conjugate, in which the biocompatible material, the non-peptidyl polymer-coupled fatty acid derivative compound, and the physiologically active polypeptide are linked, is proved, the protein conjugate may be widely used in the field of protein drugs.

Abstract: Provided is a conjugate in which an immunoglobulin Fc region is linked to an iduronate-2-sulfatase enzyme through a non-peptide polymer linker moiety. Further, provided are a conjugate, a method for preparing the same, and a composition including the same in which a non-peptide polymer linker moiety is specifically linked to an immunoglobulin Fc.

Abstract: The present invention relates to a fusion protein between a therapeutic enzyme and an immunoglobulin Fc region, a method thereof, and a composition comprising the fusion protein.

Abstract: A pharmaceutical formulation for oral administration with a controlled dissolution rate is provided. The formulation contains Tamsulosin hydrochloride-containing sustained-release pellets. The sustained-release pellets include (i) a Tamsulosin hydrochloride, (ii) hydroxypropyl methylcellulose (HPMC), (iii) an acid-resistant acryl polymer, and (iv) two or more kinds of insoluble diluents. A preparation method of the formulation is provided.